Heavy-Atom-Free Dual-Action Dual PACT/PDT action Pt(IV) Prodrug With BODIPY Dimer in Axial Position

Area of Science:

• Biochemistry
• Materials Science
• Oncology

Background:

• Photodynamic therapy (PDT) is a selective, non-invasive cancer treatment.
• Combining PDT with chemotherapy (PACT) can overcome limitations of individual therapies.
• Platinum-based chemotherapy and PDT have distinct drawbacks.

Purpose of the Study:

• To develop a dual light-controlled chemophotodynamic therapy agent.
• To create a synergistic therapeutic agent combining chemotherapy and PDT.
• To investigate a novel Pt(IV)-BODIPY conjugate for cancer treatment.

Main Methods:

• Synthesis of a Pt(IV)-BODIPY prodrug with an orthogonally arranged BODIPY dimer.
• Characterization of the prodrug's photophysical properties, including triplet state formation and singlet oxygen quantum yield.
• Evaluation of the prodrug's photosensitive toxicity in SK-BR-3 and MCF-7 tumor cells.

Main Results:

• The Pt(IV)-BODIPY agent demonstrated a long-lived, heavy-atom-free triplet state due to orthogonal fluorophore arrangement.
• High singlet oxygen quantum yield was confirmed for the dimeric fluorophore and the Pt(IV) prodrug.
• Photocontrolled toxicity was observed in relevant cancer cell lines, validating its therapeutic potential.

Conclusions:

• The developed Pt(IV)-BODIPY agent is effective for dual light-controlled chemophotodynamic therapy.
• The agent exhibits promising photosensitive properties for targeted cancer treatment.
• This conjugate holds potential for developing advanced dual therapy strategies.